Canaccord raised the firm’s price target on Globus Medical to $79 from $77 and keeps a Buy rating on the shares. The firm updated its model following the release of its preliminary Q4 and 2023 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GMED:
- Globus Medical sees FY24 EPS $2.68 to $2.70, consensus $2.72
- Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
- Globus Medical reports preliminary FY23 revenue $1.57B, consensus $1.55B
- Globus Medical sees Q4 revenue $615.5M, consensus $602.26M
- Globus Medical price target lowered to $83 from $86 at Barclays
